Povucite za promjenu položaja poklopca
Koluti
Nema postova za prikaz
Oko
The honest response is to stop designing trials around inert placebos and build more credible control conditions. That means active comparators like low-dose stimulants, niacin, or sub-the****utic microdoses, combined with centralized raters who are blinded to the patient's do****g experience and kept structurally separate from the the****utic team. These designs are harder to exe****e and more expensive. They're also what the regulatory bar now requires. Sponsors who haven't internalized that yet are going to find out the hard way.
Izrežite svoj avatar
